Alzheimer’s Treatment in Brazil: How It Works – Metropolis
“`html
Leqembi Arrives in Brazil: A New Hope for AlzheimerS Patients
Table of Contents
Brazil becomes one of the first countries in Latin America too approve adn make available Leqembi, a groundbreaking new treatment for early-stage Alzheimer’s disease. This progress offers a potential lifeline to thousands of Brazilians and marks a critically important step forward in the fight against this devastating illness.
Understanding Leqembi: How it Works
Leqembi, developed by Eisai and Biogen, is a monoclonal antibody that targets and helps clear amyloid plaques, a hallmark of Alzheimer’s disease, from the brain. Unlike previous treatments that primarily addressed symptoms, Leqembi aims to address the underlying pathology of the disease. It’s administered intravenously every two weeks.
The drug works by binding to aggregated forms of amyloid-beta protein, flagging them for removal by the body’s immune system. Clinical trials have demonstrated a modest, but statistically significant, slowing of cognitive decline in patients with early-stage Alzheimer’s.
Clinical Trial Results and Efficacy
The Clarity AD trial, a Phase 3 clinical trial, showed that leqembi slowed cognitive decline by 27% compared to a placebo over 18 months. While not a cure, this represents a meaningful enhancement for patients in the early stages of the disease. It’s important to note that the trial also revealed potential side effects, discussed below.
| Metric | Leqembi Group | placebo Group |
|---|---|---|
| CDR-SB Score Change (18 months) | +1.21 | +1.66 |
| Percentage with Amyloid Reduction | 81% | 14% |
| Incidence of ARIA-E (Edema) | 12.5% | 1.8% |
Source: Clarity AD trial data, published in the New England Journal of Medicine.
Cost and Accessibility in Brazil
The initial cost of Leqembi in brazil is significant, estimated at around R$18,000 (approximately $3,600 USD) per infusion. A full year of treatment could exceed R$200,000 (approximately $40,000 USD). This high cost currently limits access to patients who can afford private healthcare.
Discussions are underway between the Brazilian government and Eisai/Biogen to negotiate a price that would allow for inclusion in the Sistema Único de Saúde (SUS), Brazil’s public healthcare system. However, the timeline for this remains uncertain. The Ministry of Health will need to assess the cost-effectiveness of the drug and determine if it can be sustainably integrated into the SUS budget.